Neurocrine Biosciences announced that the FDA has granted fast track designation for NBI-98854 for the treatment of neuroleptic-induced tardive dyskinesia.
NBI-98854 is a highly-selective VMAT2 inhibitor that modulates dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines thereby reducing the likelihood of “off target” side effects. VMAT2 is a protein concentrated in the human brain that is primarily responsible for re-packaging and transporting monoamines (dopamine, norepinephrine, serotonin, and histamine) among nerve cells. NBI-98854 is designed to provide low, sustained, plasma and brain concentrations of active drug to minimize side effects associated with excessive dopamine depletion.
NBI-98854 may be useful in other disorders such as Huntington’s chorea, schizophrenia, Tourette’s syndrome, and tardive dystonia.
For more information call (858) 617-7600 or visit www.neurocrine.com.